In this PMS, we found that patients with a shorter history of dialysis were more likely to experience hypocalcemia and tended to have lower serum cCa levels, particularly in the first 12 weeks (ESM Fig. 1), but the efficacy of etelcalcetide was comparable (about 60–70%) in subgroups regardless of dialysis duration. Here, FBN2 is linked to Hypocalcemia.